Valuation : Quanterix Corporation

Market Cap 119M 102M 96.47M 87.9M 164M 11.21B 166M 1.14B 443M 5.73B 446M 436M 18.83B P/E 2026 *
-1.28x
P/E 2027 * -2.02x
Enterprise Value 119M 102M 96.47M 87.9M 164M 11.21B 166M 1.14B 443M 5.73B 446M 436M 18.83B EV / Sales 2026 *
0.83x
EV / Sales 2027 * 0.75x
Free-Float
93.68%
Yield 2026 *
-
Yield 2027 * -
1 day+1.79%
1 week-4.85%
Current month-4.49%
1 month-31.27%
3 months-27.14%
6 months-59.72%
Current year-59.91%
1 week 2.49
Extreme 2.49
2.74
1 month 2.15
Extreme 2.15
4.04
Current year 2.15
Extreme 2.15
8.77
1 year 2.15
Extreme 2.15
8.77
3 years 2.15
Extreme 2.15
29.7
5 years 2.15
Extreme 2.15
60.92
10 years 2.15
Extreme 2.15
92.57
Manager TitleAgeSince
Chief Executive Officer 59 19/01/2026
Director of Finance/CFO 50 22/06/2026
Chief Operating Officer - 14/05/2026
Director TitleAgeSince
Director/Board Member 63 06/06/2022
Chairman 64 24/03/2025
Director/Board Member 48 19/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
19/08/26 Exercice

Director

7,910 0.0170%
17/08/26 Exercice

Chairman

5,604 0.0121%
15/08/26 Exercice

Chief Technology Officer

3,583 0.0077%
Change 5-day change 1-year change 3-year change Capi.($)
+1.79%-4.85%-43.21%-90.17% 119M
+0.98%-4.49%+24.15%+11.67% 222B
+1.45%-2.75%+2.77%-19.71% 145B
+0.46%+0.17%-20.89%+20.60% 130B
+2.60%+2.51%-53.70%-7.35% 69.68B
+0.51%+0.50%+11.57%+20.09% 52.3B
+0.41%+0.51%-14.70%-13.41% 50.71B
+0.88%-3.02%+20.11%+26.67% 42.28B
+1.11%-1.33%+37.84%+47.88% 39.87B
+0.73%-1.24%-14.11%+51.25% 33.37B
Average +1.12%-2.11%-5.02%+4.75% 78.63B
Weighted average by Cap. +1.08%-1.59%+1.32%+8.91%

Financials

2026 *2027 *
Net sales 144M 124M 117M 106M 199M 13.59B 201M 1.38B 537M 6.95B 540M 528M 22.82B 158M 137M 129M 117M 219M 14.95B 221M 1.52B 591M 7.64B 594M 581M 25.1B
Net income -92.79M -80.05M -75.41M -68.7M -128M -8.77B -129M -893M -346M -4.48B -348M -341M -14.72B -70.09M -60.46M -56.96M -51.9M -97M -6.62B -97.73M -674M -262M -3.38B -263M -257M -11.12B
Net Debt - -
Logo Quanterix Corporation
Quanterix Corporation is a life sciences company. The Company is focused on ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development proprietary digital Simoa detection technology enables customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Its Simoa bead-based digital immunoassays utilize the basic principles of conventional bead-based sandwich ELISA. The HD-X is the Company's flagship instrument that empowers biomarker research and accelerates drug development. Its SR-X instrument is a compact benchtop instrument with a lower price point, more flexible assay preparation, and a wider range of applications. The Company's Spatial Biology solutions measure protein expression and cellular phenotypes within intact tissue while preserving spatial context and tissue architecture.
Employees
450
Date Price Change Volume
02/09/26 $2.550 +1.59% 154,308
01/09/26 $2.510 -5.99% 905,328
31/08/26 $2.670 +1.14% 408,304
28/08/26 $2.640 0.00% 349,694
27/08/26 $2.640 -1.49% 413,426
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
2.510USD
Average target price
3.000USD
Spread / Average Target
+19.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. QTRX Stock